Serum levels of interleukin 17 and 22 in patients with systemic sclerosis: a single-center cross-sectional study

Kardum, Željka; Milas-Ahić, Jasminka; Šahinović, Ines; Masle, Ana Marija; Uršić, Dora; Kos, Martina

doi:10.1007/s00296-022-05250-w

Cited by 8 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant upregulation of IL-22, but not IL-17 in the serum of AD patients, was reported to correlate with AD severity [22]. Increased production of IL-22 was also demonstrated in other dermatological conditions, including psoriasis [13,23], systemic sclerosis [24], and squamous cell carcinoma [25].…”

Section: T Helper Cellsmentioning

confidence: 97%

Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments

Makowska

Nowaczyk

Blicharz

et al. 2023

IJMS

View full text Add to dashboard Cite

Atopic dermatitis is a chronic, recurrent inflammatory skin disorder manifesting by eczematous lesions and intense pruritus. Atopic dermatitis develops primarily as a result of an epidermal barrier defect and immunological imbalance. Advances in understanding these pathogenetic hallmarks, and particularly the complex role of interleukins as atopic dermatitis drivers, resulted in achieving significant therapeutic breakthroughs. Novel medications involve monoclonal antibodies specifically blocking the function of selected interleukins and small molecules such as Janus kinase inhibitors limiting downstream signaling to reduce the expression of a wider array of proinflammatory factors. Nevertheless, a subset of patients remains refractory to those treatments, highlighting the complexity of atopic dermatitis immunopathogenesis in different populations. In this review, we address the immunological heterogeneity of atopic dermatitis endotypes and phenotypes and present novel interleukin-oriented therapies for this disease.

show abstract

Section: T Helper Cellsmentioning

confidence: 97%

Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments

Makowska

Nowaczyk

Blicharz

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Among class I and II helical cytokines, serum from SSc patients was reported to be characterized by considerably higher values of IL13, IL4, IL10 [ 142 , 143 ], IL6 (which positively correlated with both PAH and cardiac involvement) [ 144 , 145 ], IL22 [ 146 ], and IL35 [ 147 , 148 ], which was particularly increased in patients with an early NVC pattern [ 148 ]. In other studies, IL1β and IL13 have also been recorded to be significantly elevated in the serum and plasma of lcSSc patients with PAH [ 32 , 149 ], while IL6 levels, even if not significantly different between SSc and controls, were found to be lower in patients with DUs compared to those without [ 150 ].…”

Section: Cytokinesmentioning

confidence: 99%

Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review

Fioretto

Rosa

Matucci‐Cerinic

et al. 2023

IJMS

View full text Add to dashboard Cite

Systemic sclerosis (SSc, scleroderma) is a multifaceted rare connective tissue disease whose pathogenesis is dominated by immune dysregulation, small vessel vasculopathy, impaired angiogenesis, and both cutaneous and visceral fibrosis. Microvascular impairment represents the initial event of the disease, preceding fibrosis by months or years and accounting for the main disabling and/or life-threatening clinical manifestations, including telangiectasias, pitting scars, periungual microvascular abnormalities (e.g., giant capillaries, hemorrhages, avascular areas, ramified/bushy capillaries) clinically detectable by nailfold videocapillaroscopy, ischemic digital ulcers, pulmonary arterial hypertension, and scleroderma renal crisis. Despite a variety of available treatment options, treatment of SSc-related vascular disease remains problematic, even considering SSc etherogenity and the quite narrow therapeutic window. In this context, plenty of studies have highlighted the great usefulness in clinical practice of vascular biomarkers allowing clinicians to assess the evolution of the pathological process affecting the vessels, as well as to predict the prognosis and the response to therapy. The current narrative review provides an up-to-date overview of the main candidate vascular biomarkers that have been proposed for SSc, focusing on their main reported associations with characteristic clinical vascular features of the disease.

show abstract

“…Recent studies have shown how vast and ever-expanding the field of biomarkers is in SSc. Biomarkers will become increasingly important in research and, consequently, in the diagnosis and therapeutic approach to SSc [30][31][32][33][34][35][36][59][60][61][62][63][64][65][66][67]. Several studies have demonstrated the involvement of at least 240 pathways and numerous dysregulated proteins in the pathogenesis of SSc, so the field of biomarkers in this disease is complex and evolving [30][31][32][33][34][35][36][59][60][61][62][63][64][65][66][67].…”

Section: Biomarkers In Systemic Sclerosismentioning

confidence: 99%

“…Biomarkers will become increasingly important in research and, consequently, in the diagnosis and therapeutic approach to SSc [30][31][32][33][34][35][36][59][60][61][62][63][64][65][66][67]. Several studies have demonstrated the involvement of at least 240 pathways and numerous dysregulated proteins in the pathogenesis of SSc, so the field of biomarkers in this disease is complex and evolving [30][31][32][33][34][35][36][59][60][61][62][63][64][65][66][67]. Cytokeratin 17 (CK17), marginal zone protein B1 (MZB1), and leucine-rich α2-glycoprotein-1 (LRG1) appear to be potential biomarkers for SSc, with CK17 negatively associated with disease severity and higher values of CK17 protective [37,[59][60][61][62][63][64][65][66][67].…”

Section: Biomarkers In Systemic Sclerosismentioning

confidence: 99%

“…Supporting this evidence is the response of some SSc patients to B-cell-targeted therapies and the role of activated B cells in the success of allogeneic bone marrow transplantation for the treatment of SSc [24,25,[55][56][57][58][59][60]. In addition, SSc patients have macro-and microvascular damage and impaired peripheral blood perfusion [6,[48][49][50][51][52][53].…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Biomarkers in Systemic Sclerosis: An Overview

Di Maggio,

Confalonieri,

Salton

et al. 2023

CIMB

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by significant fibrosis of the skin and internal organs, with the main involvement of the lungs, kidneys, heart, esophagus, and intestines. SSc is also characterized by macro- and microvascular damage with reduced peripheral blood perfusion. Several studies have reported more than 240 pathways and numerous dysregulation proteins, giving insight into how the field of biomarkers in SSc is still extremely complex and evolving. Antinuclear antibodies (ANA) are present in more than 90% of SSc patients, and anti-centromere and anti-topoisomerase I antibodies are considered classic biomarkers with precise clinical features. Recent studies have reported that trans-forming growth factor β (TGF-β) plays a central role in the fibrotic process. In addition, interferon regulatory factor 5 (IRF5), interleukin receptor-associated kinase-1 (IRAK-1), connective tissue growth factor (CTGF), transducer and activator of transcription signal 4 (STAT4), pyrin-containing domain 1 (NLRP1), as well as genetic factors, including DRB1 alleles, are implicated in SSc damage. Several interleukins (e.g., IL-1, IL-6, IL-10, IL-17, IL-22, and IL-35) and chemokines (e.g., CCL 2, 5, 23, and CXC 9, 10, 16) are elevated in SSc. While adiponectin and maresin 1 are reduced in patients with SSc, biomarkers are important in research but will be increasingly so in the diagnosis and therapeutic approach to SSc. This review aims to present and highlight the various biomarker molecules, pathways, and receptors involved in the pathology of SSc.

show abstract

Serum levels of interleukin 17 and 22 in patients with systemic sclerosis: a single-center cross-sectional study

Cited by 8 publications

References 32 publications

Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments

Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments

Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review

Biomarkers in Systemic Sclerosis: An Overview

Contact Info

Product

Resources

About